The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial Results
Abstract
PURPOSE: Docetaxel and capecitabine, a tumor-activated oral fluoropyrimidine, show high single-agent efficacy in metastatic breast cancer (MBC) and synergy in preclinical studies. This international phase III trial compared efficacy and tolerability of capecitabine/docetaxel therapy with single-agent docetaxel in anthracycline-pretreated patients with MBC. PATIENTS AND METHODS: Patients were randomized to 21-day cycles of oral capecitabine 1,250 mg/m 2 twice daily on days 1 to 14 plus docetaxel 75 mg/m 2 on day 1 (n = 255) or to docetaxel 100 mg/m 2 on day 1 (n = 256). RESULTS: Capecitabine/docetaxel resulted in significantly superior efficacy in time to disease progression (TTP) (hazard ratio, 0.652; 95% confidence interval [CI], 0.545 to 0.780; P = .0001; median, 6.1 v 4.2 months), overall survival (hazard ratio, 0.775; 95% CI, 0.634 to 0.947; P = .0126; median, 14.5 v 11.5 months), and objective tumor response rate (42% v 30%, P = .006) compared with docetaxel. Gastrointestinal side effects and hand-foot syndrome were more common with combination therapy, whereas myalgia, arthralgia, and neutropenic fever/sepsis were more common with single-agent docetaxel. More grade 3 adverse events occurred with combination therapy (71% v 49%, respectively), whereas grade 4 events were slightly more common with docetaxel (31% v 25% with combination). CONCLUSION: The significantly superior TTP and survival achieved with the addition of capecitabine to docetaxel 75 mg/m 2, with the manageable toxicity profile, indicate that this combination provides clear benefits over single-agent docetaxel 100 mg/m 2. Docetaxel/capecitabine therapy is an important treatment option for women with anthracycline-pretreated MBC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Interpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B., & Pater, J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 2,961
Miwa, M., Ura, M., Nishida, M., Sawada, N., Ishikawa, T., Mori, K., Shimma, N., Umeda, I., & Ishitsuka, H. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00058-6 · Cited by 1,240
Introduction to sample size determination and power analysis for clinical trials
Lachin, J. M. (1981) · Controlled Clinical Trials · doi:10.1016/0197-2456(81)90001-5 · Cited by 1,012
Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast Cancer
Blum, J. L., Jones, S. E., Buzdar, A. U., LoRusso, P. M., Kuter, I., Vogel, C., Osterwalder, B., Burger, H.-U., Brown, C. S., & Griffin, T. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.485 · Cited by 783
Self-citationThe interpretation of scores from the EORTC quality of life questionnaire QLQ-C30
King, M. T. (1996) · Quality of Life Research · doi:10.1007/bf00439229 · Cited by 666
Sch�ller, J., Cassidy, J., Dumont, E., Roos, B., Banken, L., Mori, K., Reigner, B., Utoh, M., Weidekamm, E., & Durston, S. (2000) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050043 · Cited by 534
Nabholtz, J.-M., Senn, H. J., Bezwoda, W. R., Melnychuk, D., Deschênes, L., Douma, J., Vandenberg, T. A., Rapoport, B., Rosso, R., Trillet-Lenoir, V., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1413 · Cited by 508
Sawada, N., Ishikawa, T., Fukase, Y., Nishida, M., Yoshikubo, T., & Ishitsuka, H. (1998) · PubMed · Cited by 422
Blum, J. L., Dieras, V., Lo Russo, P. M., Horton, J., Rutman, O., Buzdar, A., & Osterwalder, B. (2001) · Cancer · doi:10.1002/1097-0142(20011001)92:7<1759::aid-cncr1691>3.0.co;2-a · Cited by 398
Cited by
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Matera, J., Miller, M. C., Reuben, J. M., Doyle, G. V., Allard, W. J., Terstappen, L. W. M. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040766 · Cited by 4,593
Functional Nanomaterials for Phototherapies of Cancer
Cheng, L., Wang, C., Feng, L., Yang, K., & Liu, Z. (2014) · Chemical Reviews · doi:10.1021/cr400532z · Cited by 2,425
Benson, A. B., Abrams, T. A., Ben-Josef, E., Bloomston, P. M., Botha, J. F., Clary, B. M., Covey, A., Curley, S. A., D'Angelica, M. I., Davila, R., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0027 · Cited by 2,268
Smith, T. J., Khatcheressian, J., Lyman, G. H., Ozer, H., Armitage, J. O., Balducci, L., Bennett, C. L., Cantor, S. B., Crawford, J., Cross, S. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.4451 · Cited by 1,636
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0016 · Cited by 1,584
Awareness and current knowledge of breast cancer
Akram, M., Iqbal, M., Daniyal, M., & Khan, A. U. (2017) · Biological Research · doi:10.1186/s40659-017-0140-9 · Cited by 1,406
Depression and anxiety in women with early breast cancer: five year observational cohort study
Burgess, C., Cornelius, V., Love, S., Graham, J., Richards, M., & Ramirez, A. (2005) · BMJ · doi:10.1136/bmj.38343.670868.d3 · Cited by 1,334
Cortes, J., O'Shaughnessy, J., Loesch, D., Blum, J. L., Vahdat, L. T., Petrakova, K., Chollet, P., Manikas, A., Diéras, V., Delozier, T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60070-6 · Cited by 1,094
Self-citationAapro, M. S., Bohlius, J., Cameron, D. A., Lago, L. D., Donnelly, J. P., Kearney, N., Lyman, G. H., Pettengell, R., Tjan-Heijnen, V. C., Walewski, J., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2010.10.013 · Cited by 1,090
Miles, D. W., Chan, A., Dirix, L. Y., Cortés, J., Pivot, X., Tomczak, P., Delozier, T., Sohn, J. H., Provencher, L., Puglisi, F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6457 · Cited by 897
Self-citationExtending Survival with Chemotherapy in Metastatic Breast Cancer
O'Shaughnessy, J. (2005) · The Oncologist · doi:10.1634/theoncologist.10-90003-20 · Cited by 668
Self-citationWalko, C. M., & Lindley, C. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.01.005 · Cited by 659
Cardoso, F., Fallowfield, L., Costa, A., Castiglione, M., & Senkus, E. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr372 · Cited by 596
Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer
Jones, S. E., Erban, J., Overmoyer, B., Budd, G. T., Hutchins, L., Lower, E., Laufman, L., Sundaram, S., Urba, W. J., Pritchard, K. I., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.027 · Cited by 547
Self-citationGiordano, S. H., Buzdar, A. U., Smith, T. L., Kau, S., Yang, Y., & Hortobagyi, G. N. (2004) · Cancer · doi:10.1002/cncr.11859 · Cited by 540
Aapro, M. S., Cameron, D. A., Pettengell, R., Bohlius, J., Crawford, J., Ellis, M., Kearney, N., Lyman, G. H., Tjan-Heijnen, V. C., Walewski, J., et al. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.05.002 · Cited by 539
Current approaches in treatment of triple-negative breast cancer.
Wahba, H. A., & El-Hadaad, H. A. (2015) · PubMed · doi:10.7497/j.issn.2095-3941.2015.0030 · Cited by 538
Multiple-Treatments Meta-analysis of Chemotherapy and Targeted Therapies in Advanced Breast Cancer
Mauri, D., Polyzos, N. P., Salanti, G., Pavlidis, N., & Ioannidis, J. P. A. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn414 · Cited by 523
nab-Paclitaxel mechanisms of action and delivery
Yardley, D. A. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.05.041 · Cited by 508
Cardoso, F., Harbeck, N., Fallowfield, L., Kyriakides, S., & Senkus, E. (2012) · Annals of Oncology · doi:10.1093/annonc/mds232 · Cited by 485
Thomas, E. S., Gomez, H. L., Li, R. K., Chung, H.-C., Fein, L. E., Chan, V. F., Jassem, J., Pivot, X. B., Klimovsky, J. V., de Mendoza, F. H., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.6557 · Cited by 481
Chan, S., Scheulen, M. E., Johnston, S., Mross, K., Cardoso, F., Dittrich, C., Eiermann, W., Hess, D., Morant, R., Semiglazov, V., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.66.130 · Cited by 468
Chia, S. K., Speers, C. H., D'yachkova, Y., Kang, A., Malfair‐Taylor, S., Barnett, J., Coldman, A., Gelmon, K. A., O'Reilly, S. E., & Olivotto, I. A. (2007) · Cancer · doi:10.1002/cncr.22867 · Cited by 465
Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer
Bear, H. D., Tang, G., Rastogi, P., Geyer, C. E., Robidoux, A., Atkins, J. N., Baez-Diaz, L., Brufsky, A. M., Mehta, R. S., Fehrenbacher, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1111097 · Cited by 461
Carlson, R. W., Allred, D. C., Anderson, B. O., Burstein, H. J., Carter, W. B., Edge, S. B., Erban, J. K., Farrar, W. B., Goldstein, L. J., Gradishar, W. J., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0012 · Cited by 450
Albain, K. S., Nag, S. M., Calderillo-Ruiz, G., Jordaan, J. P., Llombart, A. C., Pluzanska, A., Rolski, J., Melemed, A. S., Reyes-Vidal, J. M., Sekhon, J. S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.9362 · Cited by 425
Self-citationBreast Cancer With Synchronous Metastases: Trends in Survival During a 14-Year Period
Andre, F., Slimane, K., Bachelot, T., Dunant, A., Namer, M., Barrelier, A., Kabbaj, O., Spano, J. P., Marsiglia, H., Rouzier, R., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.095 · Cited by 394
Health state utilities for metastatic breast cancer
Lloyd, A., Nafees, B., Narewska, J., Dewilde, S., & Watkins, J. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603326 · Cited by 354
André, F., & Zielinski, C. C. (2012) · Annals of Oncology · doi:10.1093/annonc/mds195 · Cited by 329
Caswell-Jin, J. L., Plevritis, S. K., Tian, L., Cadham, C. J., Xu, C., Stout, N. K., Sledge, G. W., Mandelblatt, J. S., & Kurian, A. W. (2018) · JNCI Cancer Spectrum · doi:10.1093/jncics/pky062 · Cited by 315
Docetaxel for treatment of solid tumours: a systematic review of clinical data
Montero, A., Fossella, F., Hortobagyi, G., & Valero, V. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70094-2 · Cited by 311
Single agent versus combination chemotherapy for metastatic breast cancer
Carrick, S., Parker, S., Thornton, C., Ghersi, D., Simes, J., & Wilcken, N. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003372.pub3 · Cited by 305
Fumoleau, P., Largillier, R., Clippe, C., Dièras, V., Orfeuvre, H., Lesimple, T., Culine, S., Audhuy, B., Serin, D., Curé, H., et al. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2003.11.007 · Cited by 305
Self-citationLi, X., Shan, J., Zhang, W., Su, S., Yuwen, L., & Wang, L. (2017) · Small · doi:10.1002/smll.201602660 · Cited by 301
Pegram, M. D., Pienkowski, T., Northfelt, D. W., Eiermann, W., Patel, R., Fumoleau, P., Quan, E., Crown, J., Toppmeyer, D., Smylie, M., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh133 · Cited by 271
Self-citationOral cancer treatment: developments in chemotherapy and beyond
O'Neill, V. J., & Twelves, C. J. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600591 · Cited by 269
Self-citationThird consensus on medical treatment of metastatic breast cancer
Beslija, S., Bonneterre, J., Burstein, H. J., Cocquyt, V., Gnant, M., Heinemann, V., Jassem, J., Köstler, W. J., Krainer, M., Menard, S., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp261 · Cited by 263
Docetaxel-related side effects and their management
Baker, J., Ajani, J., Scotté, F., Winther, D., Martin, M., Aapro, M. S., & von Minckwitz, G. (2009) · European Journal of Oncology Nursing · doi:10.1016/j.ejon.2008.10.003 · Cited by 261
Guidance on the management of diarrhoea during cancer chemotherapy
Andreyev, J., Ross, P., Donnellan, C., Lennan, E., Leonard, P., Waters, C., Wedlake, L., Bridgewater, J., Glynne-Jones, R., Allum, W., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70006-3 · Cited by 257
Andreopoulou, E., & Sparano, J. A. (2013) · Current Breast Cancer Reports · doi:10.1007/s12609-012-0097-1 · Cited by 65
Therapeutic options for metastatic breast cancer
Morris, P. G., McArthur, H. L., & Hudis, C. A. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560902834961 · Cited by 59
Metadata
- Authors
- O’Shaughnessy, J., Miles, D., Vukelja, S., Moiseyenko, V., Ayoub, J.-P., Cervantes, G., Fumoleau, P., Jones, S., Lui, W.-Y., Mauriac, L., Twelves, C., Van Hazel, G., Verma, S., & Leonard, R.
- Venue
- Journal of Clinical Oncology
- Published
- 2002-06-15
- Volume
- 20
- Issue
- 12
- Pages
- 2812-2823
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2131770017
- Cited by
- 1,081
- References
- 17
- FWCI
- 32.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.